Six slide summary of challenge of AMR and the case for a de-linked funding model for new antibiotics as being piloted in the UK

1. 10 million lives a year could be lost as a
result of AMR by 2050, exceeding the
current number of deaths a year caused
by cancer (8.2 million)
AMR is one of the key
global health issues facing
our generation
10M
deaths by AMR deaths by cancer
8.5M
VS

2. Few pharmaceutical companies have
sustained focus on R&D, to produce
novel antimicrobials because of
low returns
New antimicrobials are
urgently needed to address
growing resistance, however
there are relatively few in
development

3. Using a de-linked funding model such as a
subscription model that de-links
prescription from payment, to encourage
development of new antimicrobials.
The market for novel
antimicrobials is broken –
new financing incentives
are required

4. Selection of
candidate drugs
This is being piloted in the
UK by the NHS model,
which involves

5. Use of UK institute NICE’s new innovative
health technology evaluation process to
estimate value
Valuation
This is being piloted in the
UK by the NHS model,
which involves
NICE

6. Companies are paid on a subscription basis
for three to 10 years, regardless of how
much novel antibiotics are used.
Contracting
This is being piloted in the
UK by the NHS model,
which involves